Alabama Patent of the Month – May 2024

Serina Therapeutics, Inc. is pioneering an innovative approach to treat dopamine insufficiency in conditions such as Parkinson’s disease and restless leg syndrome. Their newly patented invention utilizes poly(oxazoline) (POZ) polymer conjugates to deliver therapeutic agents with remarkable precision and control. By employing a water-soluble POZ polymer linked to a dopamine-related agent, Serina’s method ensures a customizable release profile that can be fine-tuned based on the polymer’s characteristics.

This breakthrough addresses significant challenges in dopamine-related therapies, where traditional medications often suffer from short half-lives and fluctuating blood levels, leading to inconsistent therapeutic effects and increased side effects. The POZ polymer conjugates offer a sustained, steady release of medication, maintaining therapeutic levels in the bloodstream over extended periods. This not only enhances the efficacy of the treatment but also minimizes the “pulsatile” stimulation of dopamine receptors, which is known to exacerbate motor fluctuations and dyskinesias in Parkinson’s patients.

Serina’s approach is versatile, covering a range of therapeutic agents such as dopamine agonists, adenosine A2A antagonists, anticholinergics, monoamine oxidase-B inhibitors, and catechol-O-methyl transferase inhibitors. The ability to administer these conjugates via subcutaneous injection makes the treatment less invasive and more manageable for patients.

The innovation lies in the cleavable linker within the POZ polymer, which releases the therapeutic agent in response to physiological conditions, ensuring targeted and timed delivery. This method not only enhances drug solubility and bioavailability but also reduces the frequency of dosing, significantly improving patient compliance and quality of life.

Serina Therapeutics’ groundbreaking work with POZ polymer conjugates marks a significant advancement in the management of dopamine-related disorders, promising more effective and patient-friendly treatment options in the future.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts